Find Capivasertib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Azd5363, 1143532-39-1, Azd-5363, Azd 5363, (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.9  g/mol
InChI Key
JDUBGYFRJFOXQC-KRWDZBQOSA-N
FDA UNII
WFR23M21IE

Capivasertib
Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.
1 2D Structure

Capivasertib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
2.1.2 InChI
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
2.1.3 InChI Key
JDUBGYFRJFOXQC-KRWDZBQOSA-N
2.1.4 Canonical SMILES
C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
2.1.5 Isomeric SMILES
C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
2.2 Other Identifiers
2.2.1 UNII
WFR23M21IE
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

2. Azd5363

2.3.2 Depositor-Supplied Synonyms

1. Azd5363

2. 1143532-39-1

3. Azd-5363

4. Azd 5363

5. (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

6. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

7. Wfr23m21ie

8. 4-piperidinecarboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-

9. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide

10. Unii-wfr23m21ie

11. Chembl2325741

12. Cc-638

13. Capivasertib?

14. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

15. 4-piperidinecarboxamide, 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-

16. Capivasertib (jan/usan)

17. Capivasertib [inn]

18. Capivasertib [jan]

19. Capivasertib [usan]

20. Capivasertib (azd5363)

21. Mls006011179

22. Capivasertib [who-dd]

23. Schembl390243

24. Gtpl7709

25. Azc5363

26. Dtxsid40150710

27. Ex-a285

28. Us10654855, Example 9

29. Bdbm443385

30. Mfcd22628785

31. Nsc764039

32. Nsc782347

33. Nsc799347

34. S8019

35. Zinc43204023

36. Akos027323693

37. Bcp9000365

38. Ccg-268989

39. Cs-1284

40. Db12218

41. Nsc-764039

42. Nsc-782347

43. Nsc-799347

44. Ncgc00345795-01

45. Ncgc00345795-04

46. Ac-32685

47. Hy-15431

48. Smr004702948

49. Bcp0726000111

50. A1387

51. Sw220158-1

52. D11371

53. J-514447

54. Q27074756

55. 0xz

56. 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1- (1h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

57. Alternative Route 1: (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

2.4 Create Date
2009-04-28
3 Chemical and Physical Properties
Molecular Weight 428.9 g/mol
Molecular Formula C21H25ClN6O2
XLogP31.7
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass428.1727518 g/mol
Monoisotopic Mass428.1727518 g/mol
Topological Polar Surface Area120 Ų
Heavy Atom Count30
Formal Charge0
Complexity580
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of breast cancer , Treatment of prostate cancer


API SUPPLIERS

read-more
read-more

01

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.


Lead Product(s): Capivasertib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 25, 2024

blank

01

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor, is being investigated for PTEN-deficient de novo mHSPC in combination with abiraterone and ADT.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 25, 2024

blank

Details:

Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of AKT1/2/3. It is being evaluated for the treatment of locally advanced or metastatic triple-negative breast cancer.


Lead Product(s): Capivasertib,Paclitaxel

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 18, 2024

blank

02

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of AKT1/2/3. It is being evaluated for the treatment of locally advanced or metastatic triple-negative breast cancer.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 18, 2024

blank

Details:

Truqap (capivasertib) is a first-in-class AKT inhibitor approved in combination with fulvestrant for advanced HR-positive breast cancer treatment.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2024

blank

03

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class AKT inhibitor approved in combination with fulvestrant for advanced HR-positive breast cancer treatment.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 29, 2024

blank

Details:

Truqap (capivasertib) is an ATP-competitive inhibitor of all AKT isoforms, approved in combination with Faslodex (fulvestrant) for advanced HR-positive breast cancer treatment.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2024

blank

04

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is an ATP-competitive inhibitor of all AKT isoforms, approved in combination with Faslodex (fulvestrant) for advanced HR-positive breast cancer treatment.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 27, 2024

blank

Details:

Truqap (capivasertib) is a first-in-class ATP-competitive inhibitor of all three AKT isoforms, approved with Faslodex (fulvestrant) for advanced HER2-/HR+ breast cancer treatment.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: AstraZeneca

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2024

blank

05

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class ATP-competitive inhibitor of all three AKT isoforms, approved with Faslodex (fulvestrant) for advanced HER2-/HR+ breast cancer treatment.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 27, 2024

blank

Details:

Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: AstraZeneca

Deal Size: $275.0 million Upfront Cash: $5.0 million

Deal Type: Collaboration November 22, 2023

blank

06

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Truqap, a first-in-class AKT inhibitor, discovered by AstraZeneca subsequent to its collaboration with Astex, recently approved by FDA in combination with Faslodex, for treatment for adult patients with HR-positive, HER2-negative, locally advanced or met...

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : $5.0 million

November 22, 2023

blank

Details:

Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: AstraZeneca

Deal Size: $275.0 million Upfront Cash: $5.0 million

Deal Type: Collaboration November 20, 2023

blank

07

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Truqap (capivasertib), a first in class, oral targeted inhibitor of the cancer-driving protein AKT, was discovered by AstraZeneca subsequent to its discovery collaboration with Astex.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : $5.0 million

November 20, 2023

blank

Details:

Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 20, 2023

blank

08

ASPEN
Not Confirmed
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 20, 2023

blank

Details:

Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 17, 2023

blank

09

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : Truqap (capivasertib) is a first-in-class, potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3). It is approved in combination with fulvestrant for the treatment of patients with advanced HR-positive breast cancer.

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 17, 2023

blank

Details:

AZD5363 (capivasertib) is an investigational orally and potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3) and in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer.


Lead Product(s): Capivasertib,Fulvestrant

Therapeutic Area: Oncology Brand Name: Truqap

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 12, 2023

blank

10

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

AstraZeneca

United Kingdom
arrow
ASPEN
Not Confirmed

Details : AZD5363 (capivasertib) is an investigational orally and potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3) and in combination with Faslodex granted Priority Review in the US for patients with advanced HR-posit...

Product Name : Truqap

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 12, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1143532-39-1 / Capivasertib API manufacturers, exporters & distributors?

Capivasertib manufacturers, exporters & distributors 1

27

PharmaCompass offers a list of Capivasertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Capivasertib manufacturer or Capivasertib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Capivasertib manufacturer or Capivasertib supplier.

PharmaCompass also assists you with knowing the Capivasertib API Price utilized in the formulation of products. Capivasertib API Price is not always fixed or binding as the Capivasertib Price is obtained through a variety of data sources. The Capivasertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Capivasertib

Synonyms

Azd5363, 1143532-39-1, Azd-5363, Azd 5363, (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

Cas Number

1143532-39-1

Unique Ingredient Identifier (UNII)

WFR23M21IE

About Capivasertib

Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.

Capivasertib Manufacturers

A Capivasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Capivasertib, including repackagers and relabelers. The FDA regulates Capivasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Capivasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Capivasertib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Capivasertib Suppliers

A Capivasertib supplier is an individual or a company that provides Capivasertib active pharmaceutical ingredient (API) or Capivasertib finished formulations upon request. The Capivasertib suppliers may include Capivasertib API manufacturers, exporters, distributors and traders.

click here to find a list of Capivasertib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Capivasertib GMP

Capivasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Capivasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Capivasertib GMP manufacturer or Capivasertib GMP API supplier for your needs.

Capivasertib CoA

A Capivasertib CoA (Certificate of Analysis) is a formal document that attests to Capivasertib's compliance with Capivasertib specifications and serves as a tool for batch-level quality control.

Capivasertib CoA mostly includes findings from lab analyses of a specific batch. For each Capivasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Capivasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Capivasertib EP), Capivasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Capivasertib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty